<p>Aura Biosciences（納斯達克代碼：AURA - 獲取免費報告）可能會在 2026 年 5 月 14 日星期四市場開盤前發佈其 2026 年第一季度的財報。分析師預計 Aura Biosciences 本季度每股收益為（$0.40）。各方可以查看公司即將發佈的 2026 年第一季度財報中的信息，以獲取關於定於 2026 年 5 月 15 日星期五上午 9:30（東部時間）的電話會議的最新細節。</p>
<p>獲取 <strong>Aura Biosciences</strong> 的提醒：</p>
<ul>
<li>3 只准備實現顯著增長的小型股</li>
</ul>
<p>Aura Biosciences（納斯達克代碼：AURA - 獲取免費報告）最近在 3 月 30 日星期一發布了其財報。公司報告本季度每股收益為（$0.37），超出市場普遍預期的（$0.43）$0.06。分析師平均預計 Aura Biosciences 本財年的每股收益為-$2，下一財年的每股收益也為-$2。</p>
<h2>Aura Biosciences 股票上漲 2.4%</h2>
<p>納斯達克代碼：AURA 的股票在星期五以$8.40 開盤。該公司的 50 日移動平均價格為$6.66，200 日移動平均價格為$6.05。該股票的市值為 5.3928 億美元，市盈率為-4.69，貝塔值為 0.37。Aura Biosciences 的 52 周低點為$4.34，52 周高點為$9.53。</p>
<h2>內部人士買賣</h2>
<p>在其他 Aura Biosciences 的新聞中，內部人士 Los Pinos Elisabet De 在 2 月 17 日星期二出售了 47,648 股公司的股票，交易平均價格為$5.06，總交易額為$241,098.88。出售後，該內部人士持有公司的 409,815 股股票，估值約為$2,073,663.90。這筆交易代表其持股減少了 10.42%。該交易已在提交給證券交易委員會的文件中披露，您可以通過此鏈接訪問。此外，內部人士 Conor Kilroy 在 2 月 17 日星期二出售了 12,079 股公司的股票，交易平均價格為$5.05，總交易額為$60,998.95。出售後，該內部人士直接持有 167,234 股公司的股票，估值約為$844,531.70。該交易使其持股減少了 6.74%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士共出售了 116,305 股公司股票，價值$611,230。目前，內部人士持有該股票的 6.30%。</p>
<h2>Aura Biosciences 的機構交易</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了對 AURA 的持股。Dynamic Technology Lab Private Ltd 在第一季度收購了 Aura Biosciences 的新股份，價值約為$137,000。Invesco Ltd.在第二季度收購了 Aura Biosciences 的新股份，價值約為$76,000。Nantahala Capital Management LLC 在第二季度將其在 Aura Biosciences 的持股增加了 67.1%。Nantahala Capital Management LLC 現在擁有 2,117,697 股公司的股票，價值$13,257,000，在上個季度又購買了 850,000 股。Ameriprise Financial Inc.在第二季度將其在 Aura Biosciences 的持股增加了 31.1%。Ameriprise Financial Inc.現在擁有 84,558 股公司的股票，價值$529,000，在上個季度又購買了 20,065 股。最後，Bridgeway Capital Management LLC 在第二季度收購了 Aura Biosciences 的新股份，價值約為$102,000。機構投資者和對沖基金目前持有公司 96.75% 的股票。</p>
<h2>分析師評級變動</h2>
<p>AURA 已成為幾份分析師報告的主題。Weiss Ratings 在 3 月 27 日星期五的報告中重申了對 Aura Biosciences 股票的 “賣出（d-）” 評級。HC Wainwright 在 4 月 29 日星期三的報告中將 Aura Biosciences 的目標價格從$22.00 上調至$24.00，並給予公司 “買入” 評級。最後，Wall Street Zen 在 4 月 4 日星期六的報告中將 Aura Biosciences 的評級從 “賣出” 上調至 “持有”。三位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，共識目標價格為$21.50。</p>
<p><strong>閲讀我們對 Aura Biosciences 的最新股票分析</strong></p>
<h2>Aura Biosciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Aura Biosciences 是一家臨牀階段的生物製藥公司，專注於開發新型病毒樣顆粒（VLP）療法以治療癌症。通過將專有的 VLP 技術與光激活染料相結合，Aura 旨在提供高度選擇性的光動力療法，針對並摧毀腫瘤細胞，同時保護健康組織。該公司的平台旨在解決眼科和非眼科環境中的實體腫瘤，利用近紅外光的精確激活來誘導局部腫瘤細胞凋亡並刺激抗腫瘤免疫反應。</p>
<p>主要產品候選藥物 AU-011 正在對患有脈絡膜黑色素瘤的患者進行評估，這是一種罕見但可能危及視力的眼癌。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Aura Biosciences 更具吸引力</li>
<li>巴菲特花了 60 年忽視科技，賬單即將到來</li>
<li>對黃金感到興奮但不確定其走勢？試試這三種方法</li>
<li>美元處於三年低點：三家出口商悄然印鈔</li>
<li>水務基礎設施：為什麼這個乏味的行業可能會變得令人興奮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Aura Biosciences 嗎？</h2>
<p>在考慮 Aura Biosciences 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Aura Biosciences 並不在名單上。</p>
<p>雖然 Aura Biosciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AURA

<p>Aura Biosciences（納斯達克代碼：AURA）定於 5 月 14 日發佈 2026 年第一季度財報，分析師預計每股虧損 0.40 美元。該公司此前報告每股虧損 0.37 美元，超出預期。當前股價為 8.40 美元，市值為 5.3928 億美元。內部交易活動中出現了大量股票出售，機構投資者持有 96.75% 的股份。分析師評級各異，普遍評級為 “持有”，目標價為 21.50 美元</p>

<p>Aura Biosciences (NASDAQ:AURA - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Aura Biosciences to post earnings of ($0.40) per share for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.</p>
<div class="lb-trans"><p>Aura Biosciences（納斯達克代碼：AURA - 獲取免費報告）可能會在 2026 年 5 月 14 日星期四市場開盤前發佈其 2026 年第一季度的財報。分析師預計 Aura Biosciences 本季度每股收益為（$0.40）。各方可以查看公司即將發佈的 2026 年第一季度財報中的信息，以獲取關於定於 2026 年 5 月 15 日星期五上午 9:30（東部時間）的電話會議的最新細節。</p>
</div><p>Get <strong>Aura Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aura Biosciences</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks Ready to Deliver Significant Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准備實現顯著增長的小型股</li>
</ul>
</div><p>Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its earnings results on Monday, March 30th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. On average, analysts expect Aura Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Aura Biosciences（納斯達克代碼：AURA - 獲取免費報告）最近在 3 月 30 日星期一發布了其財報。公司報告本季度每股收益為（$0.37），超出市場普遍預期的（$0.43）$0.06。分析師平均預計 Aura Biosciences 本財年的每股收益為-$2，下一財年的每股收益也為-$2。</p>
</div><h2>Aura Biosciences Stock Up 2.4%</h2>
<div class="lb-trans"><h2>Aura Biosciences 股票上漲 2.4%</h2>
</div><p>Shares of NASDAQ:AURA opened at $8.40 on Friday. The firm's 50 day moving average price is $6.66 and its 200 day moving average price is $6.05. The stock has a market cap of $539.28 million, a price-to-earnings ratio of -4.69 and a beta of 0.37. Aura Biosciences has a fifty-two week low of $4.34 and a fifty-two week high of $9.53.</p>
<div class="lb-trans"><p>納斯達克代碼：AURA 的股票在星期五以$8.40 開盤。該公司的 50 日移動平均價格為$6.66，200 日移動平均價格為$6.05。該股票的市值為 5.3928 億美元，市盈率為-4.69，貝塔值為 0.37。Aura Biosciences 的 52 周低點為$4.34，52 周高點為$9.53。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other Aura Biosciences news, insider Los Pinos Elisabet De sold 47,648 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $241,098.88. Following the sale, the insider owned 409,815 shares of the company's stock, valued at approximately $2,073,663.90. This trade represents a 10.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, insider Conor Kilroy sold 12,079 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $5.05, for a total transaction of $60,998.95. Following the sale, the insider directly owned 167,234 shares in the company, valued at approximately $844,531.70. The trade was a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 116,305 shares of company stock valued at $611,230 over the last three months. 6.30% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 Aura Biosciences 的新聞中，內部人士 Los Pinos Elisabet De 在 2 月 17 日星期二出售了 47,648 股公司的股票，交易平均價格為$5.06，總交易額為$241,098.88。出售後，該內部人士持有公司的 409,815 股股票，估值約為$2,073,663.90。這筆交易代表其持股減少了 10.42%。該交易已在提交給證券交易委員會的文件中披露，您可以通過此鏈接訪問。此外，內部人士 Conor Kilroy 在 2 月 17 日星期二出售了 12,079 股公司的股票，交易平均價格為$5.05，總交易額為$60,998.95。出售後，該內部人士直接持有 167,234 股公司的股票，估值約為$844,531.70。該交易使其持股減少了 6.74%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士共出售了 116,305 股公司股票，價值$611,230。目前，內部人士持有該股票的 6.30%。</p>
</div><h2>Institutional Trading of Aura Biosciences</h2>
<div class="lb-trans"><h2>Aura Biosciences 的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AURA. Dynamic Technology Lab Private Ltd acquired a new stake in Aura Biosciences during the first quarter worth approximately $137,000. Invesco Ltd. acquired a new stake in Aura Biosciences during the second quarter worth approximately $76,000. Nantahala Capital Management LLC raised its holdings in Aura Biosciences by 67.1% during the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company's stock worth $13,257,000 after purchasing an additional 850,000 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Aura Biosciences by 31.1% during the second quarter. Ameriprise Financial Inc. now owns 84,558 shares of the company's stock worth $529,000 after purchasing an additional 20,065 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in Aura Biosciences during the second quarter worth approximately $102,000. Institutional investors and hedge funds own 96.75% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了對 AURA 的持股。Dynamic Technology Lab Private Ltd 在第一季度收購了 Aura Biosciences 的新股份，價值約為$137,000。Invesco Ltd.在第二季度收購了 Aura Biosciences 的新股份，價值約為$76,000。Nantahala Capital Management LLC 在第二季度將其在 Aura Biosciences 的持股增加了 67.1%。Nantahala Capital Management LLC 現在擁有 2,117,697 股公司的股票，價值$13,257,000，在上個季度又購買了 850,000 股。Ameriprise Financial Inc.在第二季度將其在 Aura Biosciences 的持股增加了 31.1%。Ameriprise Financial Inc.現在擁有 84,558 股公司的股票，價值$529,000，在上個季度又購買了 20,065 股。最後，Bridgeway Capital Management LLC 在第二季度收購了 Aura Biosciences 的新股份，價值約為$102,000。機構投資者和對沖基金目前持有公司 96.75% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>AURA has been the topic of several analyst reports. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Aura Biosciences in a report on Friday, March 27th. HC Wainwright raised their target price on shares of Aura Biosciences from $22.00 to $24.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Aura Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 4th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $21.50.</p>
<div class="lb-trans"><p>AURA 已成為幾份分析師報告的主題。Weiss Ratings 在 3 月 27 日星期五的報告中重申了對 Aura Biosciences 股票的 “賣出（d-）” 評級。HC Wainwright 在 4 月 29 日星期三的報告中將 Aura Biosciences 的目標價格從$22.00 上調至$24.00，並給予公司 “買入” 評級。最後，Wall Street Zen 在 4 月 4 日星期六的報告中將 Aura Biosciences 的評級從 “賣出” 上調至 “持有”。三位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，共識目標價格為$21.50。</p>
</div><p><strong>Read Our Latest Stock Analysis on Aura Biosciences</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Aura Biosciences 的最新股票分析</strong></p>
</div><h2>Aura Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Aura Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.</p>
<div class="lb-trans"><p>Aura Biosciences 是一家臨牀階段的生物製藥公司，專注於開發新型病毒樣顆粒（VLP）療法以治療癌症。通過將專有的 VLP 技術與光激活染料相結合，Aura 旨在提供高度選擇性的光動力療法，針對並摧毀腫瘤細胞，同時保護健康組織。該公司的平台旨在解決眼科和非眼科環境中的實體腫瘤，利用近紅外光的精確激活來誘導局部腫瘤細胞凋亡並刺激抗腫瘤免疫反應。</p>
</div><p>The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.</p>
<div class="lb-trans"><p>主要產品候選藥物 AU-011 正在對患有脈絡膜黑色素瘤的患者進行評估，這是一種罕見但可能危及視力的眼癌。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Aura Biosciences</li>
<li>Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due</li>
<li>Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches</li>
<li>Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money</li>
<li>Water Infrastructure: Why This Boring Sector Could Get Exciting</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Aura Biosciences 更具吸引力</li>
<li>巴菲特花了 60 年忽視科技，賬單即將到來</li>
<li>對黃金感到興奮但不確定其走勢？試試這三種方法</li>
<li>美元處於三年低點：三家出口商悄然印鈔</li>
<li>水務基礎設施：為什麼這個乏味的行業可能會變得令人興奮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=AURA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aura Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Aura Biosciences 嗎？</h2>
</div><p>Before you consider Aura Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Aura Biosciences 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Aura Biosciences 並不在名單上。</p>
</div><p>While Aura Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Aura Biosciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Aura Biosciences (AURA) 將在週四公佈財報